amsonic acid (DAS)

Subscribe to Selected New Research on amsonic acid

589 relevant articles (32 outcomes, 91 trials/studies) found for this Bio-Agent

Description: RN given refers to parent cpd

Also Known As:

DAS; DASSA; DASD; 4,4'-diacetamido-2,2'-stilbene disulfonate; 4,4-diaminostilbene-2,2'-disulfonic acid; DADS; DSD acid; amsonic acid, disodium salt; amsonic acid, sodium salt

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 40

Hydrocarbons: 382

Cyclic Hydrocarbons: 2

Aromatic Hydrocarbons: 115

Benzene Derivatives: 9

Benzylidene Compounds

Stilbenes: 39

4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid: 87

amsonic acid: 589

Isocyanates: 196

Isothiocyanates: 167

4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid: 87

amsonic acid: 589

Sulfur Compounds: 82

Isothiocyanates: 167

4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid: 87

amsonic acid: 589

Experts

1.	Benvenuti, Luiz Alberto: 2 articles (10/2004 - 08/2002)
2.	Endicott, Jean: 1 article (10/2008)
3.	Harness, Jane: 1 article (10/2008)
4.	Fehnel, Sheri E: 1 article (10/2008)
5.	Williams, Valerie S L: 1 article (10/2008)
6.	Morlock, Robert J: 1 article (10/2008)
7.	Feltner, Douglas: 1 article (10/2008)
8.	Cappelleri, Joseph C: 1 article (10/2008)
9.	Caramori, Jaqueline Costa Teixeira: 1 article (05/2007)
10.	Franco, Roberto Jorge da Silva: 1 article (05/2007)

Related Diseases

1.	Rheumatoid Arthritis 03/01/2006 - "OBJECTIVE: To evaluate the Disease Activity Score (DAS) using various aggregated dimensions to quantify treatment outcome in patients with rheumatoid arthritis (RA), in order to determine the best instrument to be used as an endpoint that indicates good response in terms of EULAR response criteria and DAS28 remission criteria, and which satisfies the demands of clinical rheumatology" 09/01/2004 - "Therapies for rheumatoid arthritis (RA) may be assessed according to relative levels of measures to compare efficacy to another therapy or to a placebo, as in the American College of Rheumatology (ACR) 20%, 50%, or 70% (ACR 20 ACR 50 and ACR 70) responses, or by absolute levels of measures, as in disease activity scores (DAS), ACR criteria for remission, or "target values" of specific measures" 03/01/2007 - "Patients in remission (DAS<1.6) at the 3-year and 5-year time points were compared with patients with a persistently active rheumatoid arthritis by Wilcoxon's signed rank test" 03/01/2003 - "An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial." 08/01/2008 - "The objectives of this study were to investigate subjective outcome after upper-extremity surgeries for the patients with rheumatoid arthritis (RA) using the DASH questionnaire (Japanese version) and to investigate the influence of disease activity on the surgical outcome using the Disease Activity Score (DAS) 28-CRP(4)" Order ALL the reference details at left...
2.	Pain (Aches) 09/01/2005 - "Improvement criteria for the ACR Core Data Set are based on improvement of at least 20% in both tender and swollen joint counts, and three of the five additional measures (ACR 20), and corresponding "ACR 50," and "ACR 70." A pooled index which includes only the three patient self-report questionnaire measures from the Core Data Set, physical function, pain, and patient assessment of global status performs as well as ACR 20 or DAS to discriminate between efficacy of active versus placebo treatment in a clinical trial." 11/01/2005 - "Patients in DAS or DAS28 remission had a lower level of disease activity (fewer active joints, lower ESR) than those achieving ACR70 response; the converse was seen using pain VAS" 08/01/2008 - "Primary outcome measures were the mean weekly pain intensity and the disease activity score 28 (DAS 28); secondary outcome measures were the use of pain medication, the pain disability index (PDI), the clinical global impression (CGI) and pro-inflammatory cytokine levels, which were assessed during the study period and 3 months after the end of treatment" 08/01/2007 - "The approach includes five simple steps before the patient is seen by the physician: (1) an MDHAQ is completed by every patient at every visit; (2) scores are calculated for patient function, pain, and global estimate, with options for a self-report joint count and other scales; (3) scores are entered on flow sheets with data from prior visits, which might also include laboratory and medication information; (4) scores are compiled into an index termed Routine Assessment of Patient Index Data (RAPID), analogous to a Disease Activity Score (DAS); (5) RAPID scores are classified to guide treatment decisions" 02/01/2007 - "RESULTS: A significant positive correlation was found between patients' DAS and SA and between patients' expectation to experience pain during the surgical procedure" Order ALL the reference details at left...
3.	Neoplasms (Cancer) 10/21/1992 - "DAS resulted in a significant reduction in buccal pouch tumor frequency, buccal pouch tumor burden, buccal pouch gamma GT lesion frequency and forestomach tumor frequency" 05/01/1992 - "In comparison to the vehicle control group, DAS pretreatment significantly decreased the incidence of NNK-induced lung tumors (37.9 versus 100%) and the tumor multiplicity (0.6 versus 7.2 tumors/mouse)" 07/01/2007 - "The efficacy of the various liposomal formulations of DAS was evaluated on the basis of parameters such as incidence of tumorogenesis and total numbers and sizes of induced tumor nodules" 04/01/2008 - "Thus, this study put forward DAS as a drug that can possibly be used to treat cancers." 10/01/2006 - "DAS is known to inhibit chemically induced tumors in a number of in vivo and in vitro studies" Order ALL the reference details at left...
4.	Rheumatic Diseases (Rheumatism) 10/01/2006 - "The groups were also compared for the proportions of patients achieving European League Against Rheumatism (EULAR) good response, Disease Activity Score (DAS)28 remission and treatment terminations" 09/01/2005 - "The DAS-based European League Against Rheumatism (EULAR) response criteria were developed to measure individual response in clinical trials" 02/01/2008 - "Endpoints were based on Disease Activity Score (DAS) and European League Against Rheumatism (EULAR) responses" 12/01/2003 - "Efficacy variables were the European League Against Rheumatism (EULAR) response criteria using the Disease Activity Score (DAS 28) responder rate and the response rate according to American College of Rheumatology (ACR) criteria" 01/01/2002 - "The aim of this study was to test the applicability of 99mTc-hexamethylpropylene amine oxime (99mTc-HMPAO) labelled leukocyte joint scintigraphy in the assessment of disease activity in 21 patients with rheumatoid arthritis, and to compare leukocyte scintigraphy with the Disease Activity Score (DAS), a validated activity index developed by the European League Against Rheumatism (EULAR)" Order ALL the reference details at left...
5.	Parkinson Disease (Parkinson's Disease) 01/01/2008 - "In contrast, DA treatment might provoke FOG, and in two pivotal studies when DAs were compared to L-dopa in early stages of Parkinson's disease, the DA-treated arms experienced more FOGs" 08/01/2006 - "BACKGROUND: Dopamine agonists (DAs), which can be categorized as ergot derived and non-ergot derived, are used in the treatment of Parkinson's disease" 07/01/2003 - "OBJECTIVE: We sought to determine if patients with Parkinson's disease (PD), taking dopamine agonists (DAs) and reporting unintended sleep episodes (SEs), exhibit physiologically defined daytime sleepiness and can thus be differentiated from those taking DAs but not reporting SEs" 09/01/2008 - "Dopamine agonists (DAs) have proven efficacy as monotherapy in early Parkinson's disease (PD) for preventing motor complications such as dyskinesia and as adjunct therapy as the disease progresses" 09/01/2001 - "Dopamine agonists (DAs) have been shown to be effective as monotherapy in early stages of Parkinson's disease (PD) and as an adjunctive treatment to levodopa in advanced PD" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Antirheumatic Agents (DMARD)
2.	Dopamine Agonists (Dopamine Agonist)
3.	Methotrexate (Mexate)
4.	allyl sulfide
5.	diallyl trisulfide
6.	Levodopa (L Dopa)
7.	Testosterone (Sustanon)
8.	Lithium
9.	ametantrone (HAQ)
10.	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Light Coagulation
3.	Lasers (Laser)
4.	Transplants (Transplant)
5.	Surgical Decompression

Best Treatments:
Research Summary Report
on Rheumatoid Arthritis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1448 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>